My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Biogen Idec (NQ:BIIB)

182.04 +1.29 (+0.71%)

Streaming Delayed Price Updated: 12:41 PM EST, Dec 4, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

56 57 Next >

New Study Reveals How Classical Music Could Revolutionize Depression Care

August 12, 2024

In a groundbreaking study, Chinese scientists have revealed that classical music could be a powerful tool in the fight against treatment-resistant depression, a condition that affects nearly 50% of...

Via PressReach

A Blood Test Could Detect Early Alzheimer's. That Could Make These 2 Stocks Red-Hot Buys. ↗

August 11, 2024

These companies have approved Alzheimer's treatments that could generate billions in revenue for their respective businesses.

Via The Motley Fool

How Is The Market Feeling About Biogen? ↗

August 09, 2024

Via Benzinga

As Traumatic Brain Injuries Increase, Global Concussion Market Size Expected to Reach $10 Billion By 2032

August 09, 2024

EQNX::TICKER_START (NYSE:OGEN),(NYSE:ABT),(NASDAQ:BIIB),(NYSE:PFE),(NYSE:ABBV) EQNX::TICKER_END

Via FinancialNewsMedia

Stock Market Takes Bearish Turn; Apple, Microsoft, Meta, Amazon, AMD In Focus: Weekly Review ↗

August 02, 2024

Apple and Meta had strong results, while AI spending remains robust.

Via Investor's Business Daily

Topics Artificial Intelligence

Biogen (BIIB) Q2 2024 Earnings Call Transcript ↗

August 01, 2024

BIIB earnings call for the period ending June 30, 2024.

Via The Motley Fool

Topics Earnings

Biogen Q2 Earnings: Beats Consensus, Lifts 2024 Profit Forecast As New Drug Launches Expected To Offset Decline In Multiple Sclerosis Med Sales ↗

August 01, 2024

Biogen reported Q2 adjusted EPS of $5.28, surpassing the $4.03 consensus. Sales were $2.47 billion, narrowly beating the $2.38 billion consensus. Notable changes include a 5% drop in multiple sclerosis...

Via Benzinga

Biogen Earnings Flat; Biotech Giant Raises Guidance ↗

August 01, 2024

Sales slightly topped. Shares edged higher early Thursday.

Via Investor's Business Daily

The Analyst Verdict: Biogen In The Eyes Of 12 Experts ↗

July 29, 2024

Via Benzinga

Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings ↗

July 29, 2024

The unfolding week's market trajectory depends on earnings from bellwether tech stocks and what the Fed has to say following its July meeting.

Via Benzinga

Topics Economy

US Stocks Tumble On Economic, Geopolitical Concerns; Small Caps, Chipmakers Sink; Meta Rallies: What's Driving Markets Thursday? ↗

August 01, 2024

Markets experienced a sharp downturn, driven by heightened geopolitical tensions and economic uncertainties that negatively impacted investor risk sentiment, just a day after the Federal Open Market...

Via Benzinga

New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at The Alzheimer’s Association International Conference (AAIC)

July 30, 2024

From Biogen Inc.

Via GlobeNewswire

Wall Street Looks To Ride On Earnings Cheer As Meta Q2 Impresses Investors: Analyst Says Economic Data, Stock Performances Suggest Republican Win In November ↗

August 01, 2024

After Wednesday’s tech-led rebound amid the Federal Reserve’s rate decision, the stock market could be in for further gains. The major index futures point to a higher opening, although suggesting a...

Via Benzinga

Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease

July 30, 2024

From Biogen Inc.

Via GlobeNewswire

Europe Just Turned Down Biogen's Alzheimer's Drug. Is the Stock One to Avoid, or a Bad News Buy? ↗

July 29, 2024

Biogen stock has slipped 18% so far this year.

Via The Motley Fool

Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

July 26, 2024

Via Benzinga

Biogen/Eisai's Alzheimer's Drug Leqembi Gets 'No Go' From European Drug Regulator's Advisory Panel, Cites Serious Side Events ↗

July 26, 2024

The European Medicines Agency's CHMP has rejected the approval of Eisai and Biogen's Alzheimer's treatment lecanemab, citing concerns over its risks. Eisai plans to appeal the decision and work towards...

Via Benzinga

Biogen Stock Tumbles After European Regulators Unexpectedly Reject Alzheimer's Drug ↗

July 26, 2024

Biogen partner Eisai is planning to ask European regulators to re-examine their decision.

Via Investor's Business Daily

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

July 26, 2024

From Biogen Inc.

Via GlobeNewswire

BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

July 25, 2024

From Bragar Eagel & Squire

Via GlobeNewswire

Sage, Biogen Shelve Development Of Nervous System Disorder Drug After Data Disappoints ↗

July 24, 2024

Sage Therapeutics and Biogen will end further development of SAGE-324 in ET, focusing instead on evaluating future steps.

Via Benzinga

Sage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug Fails ↗

July 24, 2024

The companies are no longer developing their drug for essential tremor treatment.

Via Investor's Business Daily

Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor

July 24, 2024

From Sage Therapeutics, Inc.

Via Business Wire

Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst ↗

July 22, 2024

Ionis Pharmaceuticals releases positive results from Phase 1/2 study of ION582 for Angelman syndrome, showing consistent clinical improvements in communication, cognition, and motor function. Safety...

Via Benzinga

Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong ↗

July 22, 2024

Biogen previously decided against opting into Ionis' Angelman program.

Via Investor's Business Daily

BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit with the Schall Law Firm

July 22, 2024

From The Schall Law Firm

Via Business Wire

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)

July 19, 2024

From The Law Offices of Frank R. Cruz

Via Business Wire

BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit with the Schall Law Firm

July 19, 2024

From The Schall Law Firm

Via Business Wire

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen

July 18, 2024

From Faruqi & Faruqi LLP

Via GlobeNewswire

Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense ↗

July 16, 2024

Biogen has $8 billion to $10 billion in dry powder for acquisitions. Here are three names the company could examine.

Via Investor's Business Daily

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

56 57 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.